Literature DB >> 24979249

Advances in targeted therapy for osteosarcoma.

Wenya Zhou1, Mengze Hao, Xiaoling Du, Kexin Chen, Guowen Wang, Jilong Yang.   

Abstract

Osteosarcoma is an aggressive cancer in skeletal system with unknown molecular mechanisms of etiology and pathogenesis, therefore it remains a challenge for current therapeutic strategies to effectively treat osteosarcoma. The aim of this review is to give an overview of the molecular and mechanistic changes identified in recent years which might be new targets for the treatment of osteosarcoma. These molecules play important roles in different biological and pathological programs of osteosarcoma, including the altered oncogenes and tumor suppressor genes, molecules involved in tumor cell migration and invasion, angiogenesis, apoptosis and proliferation, miRNAs, and molecules involved in osteoclast function and multidrug resistance. Further research on these molecules in osteosarcoma will provide new insights into the target therapy for osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24979249

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  75 in total

1.  Expression profile of Twist, vascular endothelial growth factor and CD34 in patients with different phases of osteosarcoma.

Authors:  Pengfei Lei; Dengfeng Ding; Jie Xie; Long Wang; Qiande Liao; Yihe Hu
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

Review 2.  Epigenetic pathways regulating bone homeostasis: potential targeting for intervention of skeletal disorders.

Authors:  Jonathan A R Gordon; Martin A Montecino; Rami I Aqeilan; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Curr Osteoporos Rep       Date:  2014-12       Impact factor: 5.096

3.  Diallyl trisulfide regulates cell apoptosis and invasion in human osteosarcoma U2OS cells through regulating PI3K/AKT/GSK3β signaling pathway.

Authors:  Pan He; Zhijun Wang; Bin Sheng; Yongqiang Xu; Siyin Feng; Yan Huang; Fuqiang Gong; Liting Tang; Liming Xie
Journal:  Histol Histopathol       Date:  2020-12-29       Impact factor: 2.303

4.  Circular RNA 0001785 regulates the pathogenesis of osteosarcoma as a ceRNA by sponging miR-1200 to upregulate HOXB2.

Authors:  Shenglong Li; Yi Pei; Wei Wang; Fei Liu; Ke Zheng; Xiaojing Zhang
Journal:  Cell Cycle       Date:  2019-05-22       Impact factor: 4.534

5.  LncRNA ODRUL Contributes to Osteosarcoma Progression through the miR-3182/MMP2 Axis.

Authors:  Kun-Peng Zhu; Xiao-Long Ma; Chun-Lin Zhang
Journal:  Mol Ther       Date:  2017-07-05       Impact factor: 11.454

6.  Silencing of synaptotagmin 7 regulates osteosarcoma cell proliferation, apoptosis, and migration.

Authors:  Zhiqiang Wu; Zhengwang Sun; Rui Huang; Ding Zang; Chunmeng Wang; Xu Yan; Wangjun Yan
Journal:  Histol Histopathol       Date:  2019-10-21       Impact factor: 2.303

7.  miR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b.

Authors:  Qing Liu; Zhenting Wang; Xiaohua Zhou; Mingying Tang; Wei Tan; Tianshi Sun; Youwen Deng
Journal:  Cell Cycle       Date:  2019-10-10       Impact factor: 4.534

8.  The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression.

Authors:  Nan Cai; Wei Zhou; Lan-Lan Ye; Jun Chen; Qiu-Ni Liang; Gang Chang; Jia-Jie Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 9.  Deciphering signaling networks in osteosarcoma pathobiology.

Authors:  Christos Adamopoulos; Antonios N Gargalionis; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-06

10.  The role of fibroblast activation protein in progression and development of osteosarcoma cells.

Authors:  Liang Zhang; Li Yang; Zi-Wei Xia; Shi-Chang Yang; Wen-Hui Li; Bin Liu; Zi-Qi Yu; Peng-Fei Gong; Ya-Lin Yang; Wei-Zong Sun; Jing Mo; Gui-Shi Li; Tian-Yi Wang; Kai Wang
Journal:  Clin Exp Med       Date:  2019-11-19       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.